Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family

被引:4
|
作者
Liao, Ying [1 ]
Tu, Chunhua [2 ]
Song, Xiaoxia [1 ]
Cai, Liping [2 ]
机构
[1] Xinyu Peoples Hosp, Dept Gynecol, Xinyu 338000, Jiangxi, Peoples R China
[2] Nanchang Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, 17 Yongwai Zhengjie, Nanchang 330000, Jiangxi, Peoples R China
关键词
Chinese hereditary ovarian cancer family; Breast cancer susceptibility gene 1; 2; mutations; BRCA; 1; 2 gene screening; BREAST; REPLICATION; SERIES;
D O I
10.1007/s10815-020-01783-w
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objective Breast cancer susceptibility gene 1/2 (BRCA1/2) is the most important susceptibility gene associated with hereditary ovarian cancer (HOC). We aimed to screen BRAC1 and BRAC2 gene mutations in a member of a hereditary ovarian cancer family in China, and to analyze the structure and function of the mutant protein. Methods A typical HOC family was selected. Blood samples and pathological tissue samples were taken from the female members of the family. Blood samples from two patients with sporadic ovaries of the same pathological type were taken as a control group. After RNA extraction, PCR amplification was applied and the PCR products were directly sequenced and aligned, prediction and analysis of protein structure and molecular conformation that may be caused by BRCA1/2 mutation. Results The whole gene analysis of BRCA1 and BRCA2 in ovarian cancer patients in the family showed that there were 8 mutations in BRCA1 whole gene sequencing, including 3 nonsense mutations (2314C>T, 2543T>C, 4540T>C); two mutations have been recorded, which are associated with cervical cancer (2844C>T) and endometriosis (3345A>G); three newly discovered mutations (3780A>G, 5069A>G, 3326A>T). Among them, 3780A>G and 5069A>G caused amino acid changes, while 3326A>T mutation caused Arg mutation to stop codon. A total of 7 mutations were detected in BRCA2 whole-genome sequencing, including 5 non-significant mutations (3623A>G, 4034T>C, 4790A>G, 6740G>C, 7469A>G); one no-record mutation (1716T>A), and 1 recorded mutation (1342A>C), which was associated with breast cancer and ovarian cancer. BRCA1 (3326A>T) and BRCA2 (1342A>C) mutations were co-existing in patients (II1, II3, and II5) identified as serous adenocarcinoma grade II. Two cases of ovarian serous cystadenocarcinoma with no history of family tumors were normalized for BRCA1/2 gene sequencing. In the gene detection of III generation female, four females with BRCA2 (1342A>C) mutation were found, and one of them also carried the BRCA1 (3326A>T) mutation, who can be considered a high-risk group of HOC in this family. Online protein structure predictions revealed that BRCA1 (3326A>T) mutations mutated AGA at this site to TGA resulting in a translated Arg (arginine) mutation as a stop codon, while BRCA2 (1342A>C) mutated AAT at this site to CAT resulting in a translated Asn mutation to His. Conclusion The BRCA1 (3326A>T) and BRCA2 (1342A>C) were detected in the HOC family, which may be the susceptibility gene of the family's HOC. The BRCA1/2 gene screening may be possible to obtain high-risk populations in this family.
引用
下载
收藏
页码:1489 / 1495
页数:7
相关论文
共 50 条
  • [21] High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer
    Smirnova, T. Yu.
    Pospekhova, N. I.
    Lyubchenko, L. N.
    Tjulandin, S. A.
    Gar'kavtseva, R. F.
    Ginter, E. K.
    Karpukhin, A. V.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2007, 144 (01) : 83 - 85
  • [22] High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer
    T. Yu. Smirnova
    N. I. Pospekhova
    L. N. Lyubchenko
    S. A. Tjulandin
    R. F. Gar’kavtseva
    E. K. Ginter
    A. V. Karpukhin
    Bulletin of Experimental Biology and Medicine, 2007, 144 : 83 - 85
  • [23] Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan
    Liede, A
    Malik, IA
    Aziz, Z
    de los Rios, P
    Kwan, E
    Narod, SA
    AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (03) : 595 - 606
  • [24] BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients
    Myong Cheol Lim
    Sokbom Kang
    Sang-Soo Seo
    Sun-Young Kong
    Bo-Yon Lee
    Seon-Kyung Lee
    Sang-Yoon Park
    Journal of Cancer Research and Clinical Oncology, 2009, 135 : 1593 - 1599
  • [25] Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations Reply
    Kristeleit, Rebecca
    Oza, Amit M.
    LANCET ONCOLOGY, 2022, 23 (07): : E315 - E315
  • [26] Spectrum of BRCA1 and BRCA2 mutations in Romanian patients with ovarian cancer
    Cardos, G.
    Curtis, A.
    Lisgo, J.
    Silmon, A.
    Bucur, G.
    Nitipir, C.
    Roman, D.
    Floares, C.
    Zeleniuc, M.
    Apostol, P.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 526 - 526
  • [27] BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients
    Lim, Myong Cheol
    Kang, Sokbom
    Seo, Sang-Soo
    Kong, Sun-Young
    Lee, Bo-Yon
    Lee, Seon-Kyung
    Park, Sang-Yoon
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (11) : 1593 - 1599
  • [28] Inactivation of BRCA1 and BRCA2 in ovarian cancer
    Hilton, JL
    Geisler, JP
    Rathe, JA
    Hattermann-Zogg, MA
    DeYoung, B
    Buller, RE
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (18): : 1396 - 1406
  • [29] The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
    Ramus, Susan J.
    Gayther, Simon A.
    MOLECULAR ONCOLOGY, 2009, 3 (02) : 138 - 150
  • [30] Regional Distributions Of BRCA1 And BRCA2 Gene Mutations In Turkish Hereditary Ovarian Cancer Patients Including Balkan Turks
    Kilic, E. S.
    Kuru, G.
    Akdeniz, O. D.
    Tuncer, B.
    Erdogan, S. O.
    Avsar, M.
    Altundag, K.
    Saip, P.
    Yazici, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 80 - 80